摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl]pyrimidin-2-amine | 1029715-64-7

中文名称
——
中文别名
——
英文名称
5-[1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl]pyrimidin-2-amine
英文别名
5-[1-(oxolan-3-yl)pyrazol-4-yl]pyrimidin-2-amine
5-[1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl]pyrimidin-2-amine化学式
CAS
1029715-64-7
化学式
C11H13N5O
mdl
——
分子量
231.257
InChiKey
PYGSPIXUZSDPJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    78.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    申请人:Incyte Corporation
    公开号:US07767675B2
    公开(公告)日:2010-08-03
    The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶,以及它们的药物组合物,它们是c-Met激酶抑制剂,可用于治疗与激酶通路失调相关的癌症和其他疾病。
  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    申请人:Incyte Corporation
    公开号:US10738052B2
    公开(公告)日:2020-08-11
    The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物,它们是激酶(如 c-Met)的抑制剂,可用于治疗癌症和其他与激酶通路失调有关的疾病。
  • Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors
    申请人:Incyte Corporation
    公开号:US20180282340A1
    公开(公告)日:2018-10-04
    The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
  • US7767675B2
    申请人:——
    公开号:US7767675B2
    公开(公告)日:2010-08-03
  • US8461330B2
    申请人:——
    公开号:US8461330B2
    公开(公告)日:2013-06-11
查看更多